Prostate cancer: Current and evolving strategies

American Journal of Health-System Pharmacy

Volumn 53, Issue 4, 1996, Pages 381-396

  Cersosimo, Robert J ^a,b   Carr, Daniel ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aminoglutethimide; Antineoplastic agents; Bicalutamide; Diagnosis; Estrogens; Finasteride; Flutamide; Hormones; Ketoco nazole; Nilutamide; Progestins; Prostatic neoplasms; Radiation; Suramin

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; DIETHYLSTILBESTROL; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MEGESTROL; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MALE; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 0030027512     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.4.381     Document Type: Review

References (154)

1. Korman LB. Treatment of prostate cancer. Clin Pharm. 1989; 8:412-24.
2. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995; 45:8-30.
3. Franks LM. Latency and progression in tumors: the natural history of prostatic cancer. Lancet. 1956; 2:1037-9.
4. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol. 1992; 23:211-22.
5. Seidman H, Mushinski MH, Geib SK. Probabilities of eventually developing or dying of cancer - United States, 1985. CA Cancer J Clin. 1985; 35:35-56.
6. Lu-Yao GL, Greenberg ER. Changes in prostatic cancer incidence and treatment in USA. Lancet. 1994; 343:251-4.
7. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990; 16:187-97.
8. Steinberg GD, Carter BS, Beaty TH et al. Family history and the risk of prostate cancer. Prostate. 1990; 17:337-47.
9. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol. 1991; 30:133-40.
10. Haenzel W, Kurihara M. Studies of Japanese immigrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968; 40:43-68.
11. Staszewski J, Haenzel W. Cancer mortality among the Polish-born in the United States. J Natl Cancer Inst. 1961; 26:37-132.
12. Jackson MA, Ahluwalia BS, Herson J et al. Characterization of prostatic carcinoma among blacks: a confirmation report. Cancer Treat Rep. 1977; 61:167-72.
13. Ernster VL, Selvin S, Brown SM et al. Occupation and prostatic cancer: a review and retrospective analysis based on death certificates in two California counties. J Occup Med. 1979; 21:175-83.
14. Meikle AW, Smith JA Jr. Epidemiology of prostate cancer. Urol Clin N Am. 1990; 17:709-18.
15. Heshmat M, Kaul L, Kovi J et al. Nutrition and prostate cancer. A case-controlled study. Prostate. 1985; 6:7-17.
16. Guess HA. Is vasectomya risk factor for prostate cancer? Eur J Cancer. 1993; 29A:1055-9.
17. Kipling MD, Waterhouse JAH. Cadmium and prostate cancer. Lancet. 1967; 1:730-1.
18. Rosenberg L, Palmer JR, Zauber AG et al. Vasectomy and the risk of prostate cancer. Am J Epidemiol. 1990; 132:1051-5.
19. Mettlin C, Natarajan N, Huben R. Vasectomy and prostate cancer risk. Am J Epidemiol. 1990; 132:1056-61.
20. Spitz MR, Currier RD, Fueger JJ et al. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991; 146:1305-7.
21. Armenian HK, Lilienfeld AM, Diamond EL et al. Relation between benign prostatic hyperplasia and cancer of the prostate: a prospective and retrospective study. Lancet. 1974; 2:115-7.
22. Greenwald P, Kirmss V, Polan AK et al. Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst. 1974; 53:335-40.
23. Beral V, Inskip H, Fraser P et al. Mortality of employees of the United Kingdom Atomic Energy Authority. 1946-1979. Br Med J. 1985; 291:440-7.
24. Willett WC, Morris JS, Pressel S et al. Prediagnostic serum selenium and risk of cancer. Lancet. 1983; 2:130-4.
25. Bostwick DG, Myers RD, Osterling JE. Staging of prostate cancer. Semin Surg Oncol. 1994; 10:60-72.
26. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50:125-8.
27. Gleason DF, Mellinger GT. and Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111:58-64.
28. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the US, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993; 43:83-91.
29. Partin AW, Osterling JE. The clinical usefulness of prostate-specific antigen: update 1994. J Urol. 1994; 152:1358-68.
30. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317:909-16.
31. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993; 153:2529-37.
32. Graves HCB, Wehner N, Stamey TA. A comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard. J Urol. 1990; 144:1516-22.
33. Ercole CJ, Lange PH, Mathisen M et al. Prostate-specific antigen and prostatic acid phosphatase in monitoring and staging of patients with prostatic cancer. J Urol. 1987; 138:1181-4.
34. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol. 1989; 142:1011-7.
35. Armitage TG, Cooper EH, Newling DWW et al. The value of the measurement of prostate-specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol. 1988; 62:584-9.
36. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324:1156-61.
37. Brawer MK, Chetner MP, Beatie J et al. Screening for prostate carcinoma with prostate-specific antigen. J Urol. 1992; 147:841-5.
38. Benson MS, Whang IS, Pantuck A et al. Prostate-speciic antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147:815-6.
39. Benson MC, Whang IS, Olsson CA et al. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol. 1992; 147:817-21.
40. Brawer MK, Aranburu EAG, Chen GL et al. The inability of prostate-specific antigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostate carcinoma. J Urol. 1993; 150:369-73.
41. Jewett MAS, Jain U, Toi A et al. Prostate-specific antigen density (PSAD): can it distinguish between benign hyperplasia and malignancy? J Urol. 1993; 149:415A. Abstract.
42. Lookner DH, Crawford ED, Donohue RE et al. Prostate-specific antigen and prostate-specific antigen density in cases of pathologically proven prostate cancer. J Urol. 1993; 149:414A. Abstract.
43. Carter HB, Pearson JD, Metter JE et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267:2215-20.
44. Osterling JE, Chute CG, Jacobsen SJ et al. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. J Urol. 1993; 149:412A. Abstract.
45. Catalona WJ, Smith DS, Ratliff TL. Value of measurement of the rate of changes in serum PSA levels in prostate cancer screening. J Urol. 1993; 149:300A. Abstract.
46. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am. 1993; 20:665-70.
47. Osterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270:860-4.
48. Dalkin BL, Ahmann F, Southwick P et al. Derivation of normal prostate-specific antigen (PSA) levels by age. J Urol. 1993; 149:413A. Abstract.
49. Nooter RI, Bangma CH, Schoder FH. Age-specific reference ranges for prostate-specific antigen. JAMA. 1994; 271:746-7 Letter.
50. Osterling JE. Prostate-specific antigen: improving its ability to diagnose early prostate cancer. JAMA. 1992; 267:2236-8.
51. Lee F, Littrup PJ, Torp-Pedersen ST et al. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology. 1988; 168:389-94.
52. Lee F, Torp-Pedersen S, Littrup PJ et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology. 1989: 170:29-32.
53. Cooner WH, Mosley BR, Rutherford CL Jr et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate-specific antigen. J Urol. 1990; 143:1146-54.
54. Mettlin C, Murphy GP, Ray P et al. American Cancer Society-National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate-specific antigen. Cancer. 1993; 71:891-8.
55. Murphy GP. Report on the American Urologic Association/ American Cancer Society scientific seminar on the detection and treatment of early stage prostate cancer. CA Cancer J Clin. 1994; 44:91-5.
56. Partin AW, Pound CR, Clemens JQ et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin N Am. 1993; 20:713-25.
57. Zagars GK, Sherman NE, Babaian RJ. Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer. 1991; 67:412-20.
58. Link P, Freiha FS, Stamey TA. Adjuvant radiation therapy in patients with detectable prostate-specific antigen following radical prostatectomy. J Urol. 1991; 145:532-4.
59. Stamey TA, Kabalin JN, Ferrari M et al. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate IV. Anti-androgen treated patients. J Urol. 1989; 141:1088-90.
60. Zanetti G, Trinchieri A, DelNero A et al. Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur Urol. 1992; 21(Suppl):96-8.
61. Epstein JI, Paull G, Eggleston JC et al. Prognsis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow up. J Urol. 1986; 136:837-9.
62. Blute ML, Zincke H, Farrow GM. Long-term follow up of young patients with stage A adenocarcinoma of the prostate. J Urol. 1986; 136:840-3.
63. Blute ML, Nativ O, Zincke H et al. Pattern of failure alter radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989; 142:1262-5.
64. Cantrell BB, DeKlerl DP, Eggleston JC et al. Pathologic factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol. 1981; 125:516-20
65. Zincke H, Blute ML, Fallen MJ et al. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations. J Urol. 1991; 146:1053-8.
66. Middleton RG, Smith JA Jr. Comparison of 5 and 10 year survival following radical prostatectomy. J Urol. 1989; 141:309A. Abstract.
67. Paulson DF, Robertson CN. The relevance of stage A malignancy in prostate cancer. Acta Oncol. 1991; 30:227-9.
68. Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer Justification of long-term follow up. Urol Clin N Am. 1990; 17:787-802.
69. Hanks GE, Asbell S, Krall JM et al. Outcome for lymph node dissection negative T-1b, T-2(A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys. 1991; 21:1099-103.
70. Middleton RG, Smith JA Jr, Melzer RB et al. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol. 1986; 136:422-4.
71. Walsh PC. Radical retropubic prostatectomy with reduced morbidity: an anatomic approach. Natl Cancer Inst Monogr. 1988; 7:133-7.
72. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. Natl Cancer Inst Monogr. 1988; 7:47-60.
73. Elder JS, Hewett HJ, Walsh PC. Radical perineal prostatectomy for stage B2 carcinoma of the prostate. J Urol. 1982; 127:704-6.
74. Hanks GE. External beam radiation treatment for clinically localized prostate cancer: patterns of care studies in the United States. Natl Cancer Inst Monogr. 1988; 7:75-84.
75. Paulson DF, Lin GH, Hinshaw W et al. Radical surgery versus radiotherapy for stage A2 and stage B (T1-2 NoMo) adenocarcinoma of the prostate. J Urol. 1982; 128:502-4.
76. Devita VT, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott; 1993:1086.
77. Perez CA, Pilepich MV, Garcia D et al. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. Natl Cancer Inst Monogr. 1988; 7:85-94.
78. Zagars GK, von Eschenbach AC, Johnson DE et al. Stage C adenocarcinoma of the prostate. An analysis of 951 patients treated with external beam radiation. Cancer. 1987; 60:1489-99.
79. Holzman M, Carlton CE Jr, Scardino PT. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol. 1991; 146:1578-82.
80. Huggins C, Hughes CV. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1:293-7.
81. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr. 1988; 7:165-70.
82. Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967; 124:1011-7.
83. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973; 32:1126-30.
84. Byar DO. VACURG studies of conservative treatment. Scand J Urol Nephrol. 1980; 55:99-102.
85. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer. 1993; 71:1089-97.
86. Soloway MS, Chodak G, Vogelzang NJ et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology. 1991; 37:46-51.
87. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984; 311:1281-6.
88. Kaisary AV, Ryan PG, Turkes A et al. A comparison between surgical orchiectomy and LHRH analogue ("Zoladex," ICI 118,630) in the treatment of advanced prostate carcinoma - a multicentre clinical study. Prog Clin Biol Res. 1988; 260:89-100.
89. Turkes AO, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate: Phase III trial, Zoladex against castration; a study of the British prostate group. J Steroid Biochem. 1987; 27:543-9.
90. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and DES in treatment of prostatic carcinoma. Urology. 1989; 33(Suppl 5):45-52.
91. Vogelzang N, Citrin D, Chodak G et al. Phase III randomized trials of depot Zoladex and standard hormonal therapy in advanced prostate cancer. Proc Am Soc Clin Oncol. 1988; 7:119. Abstract.
92. Erntage LA, Trethowan C, Kelly K et al. A Phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Research Group study. Prog Clin Biol Res. 1989; 303:47-52.
93. Blackledge G, Emtage LA, Trethowan C et al. "Zoladex" depot vs. DES 3 mg/day in advanced prostate cancer. A randomized trial comparing efficacy and tolerability. J Urol. 1989; 141(4, Part 2):347A. Abstract.
94. Thompson IM, Zeidman EJ, Ridriquez FR. Sudden death due to disease flare with lutemizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990; 144:1479-80.
95. Bressler LR, Murphy CM, Shevrin DH et al. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993; 27:182-5.
96. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994; 331: 347-52.
97. Geller J. Megestrol acetate plus low-dose estrogen in the management of advanced prostate carcinoma. Urol Clin N Am. 1991; 18:83-91.
98. Geller J, Albert J, Yen SSC. Treatment of advanced cancer of the prostate with megestrol acetate. Urology. 1978; 12:537-41.
99. Geller J, Albert J, Yen SCC et al. Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. J Clin Endocrinol Metab. 1981; 52:576-80.
100. Venner P. Megestrol acetate in the treatment of metastatic carcinoma of the prostate. Oncology. 1992; 49(Suppl 2):22-7.
101. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-24.
102. Crawford ED, Smith JA, Soloway MS et al. A randomized controlled trial of leuprolide and Anadron versus leuprolide and placebo for advanced prostate cancer. J Urol. 1990; 143:221A. Abstract.
103. Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin N Am. 1991; 18:55-63.
104. Iversen P, Rasmussen F, Klarskov P et al. Long-term results of Danish Prostatic Cancer Group trial 86. Cancer. 1993; 72:3851-4.
105. Fourcade RO, Cariou G, Coloby P et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol. 1990; 18(3, Suppl):45-7.
106. Beland G. Combination of Anadron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study. Urology. 1991; 37(Suppl):25-9.
107. Denis LJ, Carneiro De Moura JL, Bono A et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993; 42:119-30.
108. Jurincic CD, Horlbeck R, Klipper K-F. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study. Semin Oncol. 1991; 18(Suppl 6):21-S.
109. Tyrrell CJ, Altwein JE, Klipper F et al. A multicenter randomized trial comparing the luteinizing hormone releasing hormone analog goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991; 146:1321-6.
110. Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anadron) or placebo as treatment of metastatic prostate cancer. Cancer. 1993; 72:3874-7.
111. Denis L, Murphy GP. Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 1993; 72(Suppl):3888-95.
112. Irwin RJ, Prout GR Jr. A new antiprostatic agent for treatment of prostatic carcinoma. Surg Forum. 1973; 24:536-7.
113. Pavone-Mancaluso M, Pavone C, Serretta V et al. Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology. 1989; 34:27-36.
114. Kassem NY, Neri RO, Muntol JS. Effect of flutamide, an antiandrogen on stage D cancer of the prostate. J Pharmacol Ther. 1981; 29:256. Abstract.
115. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol. 1988; 61:140-2.
116. Prout GR Jr, Keating MA, Griffin PP et al. Long-term experience with flutamide in patients with prostatic carcinoma. Urology. 1989; 34(Suppl):37-45.
117. Sogani PC, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer. 1984; 54:744-50.
118. Keating MA, Griffin PF, Schiff SF. Flutamide in the treatment of advanced prostate cancer. J Urol. 1986; 135:203A. Abstract.
119. Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol. 1987; 59:156-8.
120. Daricello G, Serretta V, Pavone-Macaluso M. Flutamide in the treatment of advanced prostate cancer. J Drug Dev. 1987; 1(Suppl 1):17-22.
121. Prout GR Jr, Irwin RJ Jr, Kliman B et al. Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis. J Urol. 1975; 113:834-40.
122. Delaere KPJ, Vanthillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol. 1991; 18(Suppl 6):13-8.
123. Narayana AS, Loening SA, Culp DA. Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol. 1981; 53:152-3.
124. MacFarlane JR, Tolley DA. Flutamide therapy for advanced prostatic cancer: a Phase III study. Br J Urol. 1985; 57:172-4.
125. DiSilverio F. Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. J Drug Dev. 1987; 1(Suppl 1):10-6.
126. Jacobo E, Schmidt JD, Weinstein SH et al. Comparison of flutamide (SCH 13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology. 1976; 8:231-3.
127. Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149:607-9.
128. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11:1566-72.
129. Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology. 1991; 37(Suppl):13-9.
130. DePlessis DJ. Castration plus nilutamide vs. castration plus placebo in advanced prostate cancer. A review. Urology. 1991; 37(Suppl):20-4.
131. Decensi AU, Boccardo F, Guarneri D et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol. 1991; 146:377-81.
132. Veldscholte J, Ris-Stalpers C, Kuiper GGJM et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990; 173:534-43.
133. Cockshott ID, Cooper KJ, Sweetmore DS et al. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol. 1990; 18(3, Suppl):10-7.
134. Denis L. A new nonsteroidal antiandrogen: therapeutic progress in urological cancers. Clin Biol Res. 1989; 303:95-103.
135. Kennealey GT, Fun BJA. Use of the nonsteroidal antiandrogen Casodex in advanced prostatic carcinoma. Urol Clin N Am. 1991; 18:99-110.
136. Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate. 1994; 5(Suppl):27-33.
137. Hughes SW, Burley DM. Aminoglutethimide: a "side-effect" turned to therapeutic advantage. Postgrad Med J. 1970, 46:409-16.
138. Sanford EJ, Drago JR, Rohner TJ Jr et al. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol. 1976; 115:170-4.
139. Drago JR, Santen RJ, Lipton A et al. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer. 1984; 53:1447-50.
140. Dowsett M, Shearer RJ, Ponder BAJ et al. The effects of aminoglutethimide and hydrocortisone, alone and combined on androgen levels in post-orchiectomy prostatic cancer patients. Br J Cancer. 1988; 57:190-2.
141. Plowman PN, Perry LA, Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomized men with prostatic cancer. Br J Urol. 1987; 59:253-7.
142. Tapazoglou E, Subramanian MG, Al-Sarraf M et al. High-dose ketoconazole therapy in patients with metastatic prostate cancer. Am J Clin Oncol. 1986; 9:369-75.
143. Vanuytsel L, Ang KK, Vantongelen K et al. Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J Urol. 1987; 137:905-8.
144. Moffat LEF, Kirk D, Tolley DA et al. Ketoconazole as primary treatment of prostatic cancer. Br J Urol. 1988; 61:439-40.
145. Aabo K, Kjaer M, Hansen HH. High dose ketoconazole to untreated stage D prostate cancer. Eur J Cancer. 1988; 24:431-7.
146. Pont A. Long-term experience with high-dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol. 1987; 137:902-4.
147. Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer. 1993; 71:1068-73.
148. Presti JC Jr, Fair WR, Andriole G et al. Multicenter, randomized double-blind placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. 1992; 148:1201-4.
149. Mydlo JH, Michaeli J, Heston WD et al. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate. 1988; 13:241-7.
150. Story MT, Livingston B, Bacten L et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate. 1989; 15:355-65.
151. LaRocca RV, Danesi R, Cooper MR et al. Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991; 145:393-8.
152. Myers C, Cooper M, Stein C et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992; 10:881-9.
153. Eisenberger MA, Simon R, O'Dwyer PJ et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985; 3:827-41.
154. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. 1993; 71:1098-109.